CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

Cancer Network
Original article

<![CDATA[Immunotherapy Plus iSBRT Boosts Response in PD-L1-Negative Breast Cancer]]>

Phase 2durvalumab

Read the original article

Published by Cancer Network on August 4, 2026 6:00 PM

Read Original